PFIZER INC.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 1849-01-01
- Employees
- 88K
- Market Cap
- $163.3B
- Website
- http://www.pfizer.com
Treatment With Recombinant Human Growth Hormone Genotonorm (Registered) In Children With Short Stature Secondary
Phase 3
Completed
- Conditions
- First Posted Date
- 2005-09-15
- Last Posted Date
- 2008-08-05
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 14
- Registration Number
- NCT00174278
- Locations
- 🇫🇷
Pfizer Investigational Site, Paris, France
Treatment of Adult ADHD With Atomoxetine or Atomoxetine and Buspar
Phase 2
Completed
- Conditions
- First Posted Date
- 2005-09-15
- Last Posted Date
- 2008-07-15
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 241
- Registration Number
- NCT00174226
- Locations
- 🇺🇸
Pfizer Investigational Site, Woodstock, Vermont, United States
Study To Assess Differential Sensitivity Of 2 Spatial Working Memory Tests In Schizophrenics Treated With Risperidone
Not Applicable
Completed
- Conditions
- First Posted Date
- 2005-09-15
- Last Posted Date
- 2008-07-15
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 20
- Registration Number
- NCT00174200
- Locations
- 🇷🇺
Pfizer Investigational Site, Moscow, Russian Federation
Somatropin Therapy In Children Born Preterm But Appropriate For Gestational Age
Phase 2
Completed
- Conditions
- Interventions
- First Posted Date
- 2005-09-15
- Last Posted Date
- 2017-04-05
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 33
- Registration Number
- NCT00174460
- Locations
- 🇩🇪
Pfizer Investigational Site, Tuebingen, Germany
Study to Investigate the Seropersistence of TBE Virus Antibodies Approx. 3 Years After a Booster Vaccination With FSME-IMMUN 0.25 mL JUNIOR in Children
Completed
- Conditions
- First Posted Date
- 2005-09-14
- Last Posted Date
- 2015-05-21
- Lead Sponsor
- Pfizer
- Registration Number
- NCT00163618
- Locations
- 🇦🇹
Freistädter Strasse 290, Linz, Austria
🇦🇹Bahnhofstraße 9, Hermagor, Austria
🇦🇹Conrad-von-Hoetzendorf-Strasse, Voitsberg, Austria
Immunogenicity and Safety Study of a Third Vaccination With FSME-IMMUN 0.5 mL in Subjects Previously Vaccinated According to a Rapid Immunization Schedule (Follow-up to Study 225)
Phase 4
Completed
- Conditions
- First Posted Date
- 2005-09-14
- Last Posted Date
- 2015-05-21
- Lead Sponsor
- Pfizer
- Registration Number
- NCT00163540
- Locations
- 🇧🇪
SGS Biopharma Research Unit Stuivenberg, Antwerp, Belgium
A Study of UK-369,003 on the Safety and Efficacy in Patients With COPD
Phase 1
Completed
- Conditions
- First Posted Date
- 2005-09-13
- Last Posted Date
- 2006-10-13
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 136
- Registration Number
- NCT00163098
- Locations
Pfizer Investigational Site
The Effects of an NR2B NMDA Antagonist, CP-101,606, in Patients With Parkinson's Disease
Phase 2
Completed
- Conditions
- First Posted Date
- 2005-09-13
- Last Posted Date
- 2006-09-22
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 12
- Registration Number
- NCT00163085
- Locations
- 🇺🇸
Pfizer Investigational Site, Portland, Oregon, United States
The Antidepressant Effects Of The NMDA Antagonist, CP-101,606, In Patients With MDD
Phase 2
Completed
- Conditions
- First Posted Date
- 2005-09-13
- Last Posted Date
- 2006-09-22
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 30
- Registration Number
- NCT00163059
- Locations
- 🇺🇸
Pfizer Investigational Site, Wichita, Kansas, United States
Growth Retardation In Children With Special Pathological Conditions Or Disease
- First Posted Date
- 2005-09-13
- Last Posted Date
- 2012-12-19
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 46
- Registration Number
- NCT00163215
- Locations
- 🇫🇷
Pfizer Investigational Site, Vandoeuvre Les Nancy Cedex, France
© Copyright 2024. All Rights Reserved by MedPath